Perspective Therapeutics (CATX) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($252.9 million vs $247.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | VCRE |
|---|---|---|
| Share price | $2.17 | $8.98 |
| Market cap | $247.71M | $252.92M |
| 1-day change | -7.26% | -1.21% |
| YTD return | -21.09% | — |
| 1-year return | -51.67% | — |
| 5-year return | -66.09% | — |
| EPS (TTM) | $-1.33 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-103.12M | — |
| 52-week high | $6.16 | $17.80 |
| 52-week low | $1.96 | $7.88 |
| Distance from 52-week high | -64.77% | -49.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +466.36% | +223.83% |
| Average volume | 1.58M | 17.84K |
| Shares outstanding | 114.15M | 28.16M |
| Employees | 163 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
CATX vs VCRE FAQ
Which is bigger, Perspective Therapeutics or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $252.92M compared with $247.71M for Perspective Therapeutics (CATX).
Are Perspective Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.